PCRX Q4 2025 Earnings — Pacira BioSciences, Inc. Revenue & Financial Results | Market Cap Arena

PCRXPacira BioSciences, Inc.

$971M

Q4 2025 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$197M+5.1% YoY

Gross Profit

$99M50.4% margin

Operating Income

$11M5.7% margin

Net Income

$2M0.8% margin

EPS (Diluted)

$0.04

QoQ Revenue Growth

+9.7%

Cash Flow

Operating Cash Flow

$44M

Free Cash Flow

$43M

Stock-Based Comp.

$13M

Balance Sheet

Total Assets

$1.3B

Total Liabilities

$572M

Stockholders' Equity

$693M

Cash & Equivalents

$159M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$197M	$187M	+5.1%
Gross Profit	$99M	$147M	-32.6%
Operating Income	$11M	$25M	-54.5%
Net Income	$2M	$16M	-89.8%

Revenue Segments

Product

$197M51%

EXPAREL

$156M40%

ZILRETTA

$33M9%

Bupivacaine Liposome Injectable Suspension

$1M0%